An updated survival analysis of the CRYSTAL trial, including an increased number of patients analyzed for tumor mutation status, demonstrated that the addition of cetuximab to FOLFIRI as first-line therapy improves survival in patients with KRAS wild-type (wt) mCRC [18]. The gene discussed is KRAS; the disease is neoplasm.